natgillin/translations-raw huggingface dataset:
Patients at increased risk for bleeding (for example): any major surgery, defined as surgery that requires general or spinal anesthesia, performed within the 12-hour period immediately preceding drug infusion, or any postoperative patient who demonstrates evidence of active bleeding, or any patient with planned or anticipated surgery during the drug infusion period.
Bolniki s povečanim tveganjem za krvavitev (na primer): kakršenkoli večji operacijski poseg, opredeljen kot operacijski poseg, ki zahteva splošno ali spinalno anestezijo, opravljen v 12-urnem obdobju neposredno pred infuzijo zdravila, ali katerikoli bolnik po operaciji, ki kaže znake aktivne krvavitve, ali katerikoli bolnik z načrtovanim ali pričakovanim operacijskim posegom v obdobju infuzije zdravila
Patients at low to moderate immunological risk were studied in the phase 3 ciclosporin elimination-Rapamune maintenance study, which included patients receiving a renal allograft from a cadaveric or living donor.
III. faze so bili vključeni bolniki z nizkim do zmernim imunskim tveganjem s presajeno kadavrsko ledvico ali ledvico živega darovalca.
Patients at risk for bleeding or patients at risk of overexposure, notably patients with moderate renal impairment (CrCL 30-50 mL/min), should be treated with caution (see sections 4.4 and 5.1).
Bolnike, ki jih ogroža krvavitev ali pri katerih obstaja nevarnost prevelike izpostavljenosti, predvsem tiste z zmerno ledvično okvaro (CrCl 30-50 ml/min), je treba zdraviti previdno (glejte poglavji 4.4 in 5.1).
Patients at risk of bleeding (SPAF, DVT/PE
Bolniki s povečanim tveganjem za krvavitve (SPAF, GVT/PE)
Patients at risk of renal impairment (such as patients with baseline renal risk factors, advanced HIV disease, or patients receiving concomitant nephrotoxic medications) are at increased risk of experiencing incomplete recovery of renal function despite tenofovir disoproxil fumarate discontinuation (see section 4.4).
Pri bolnikih s tveganjem ledvične okvare (kot so bolniki z dejavniki tveganja za ledvice ob izhodišču, napredovalo boleznijo HIV ali bolniki, ki sočasno prejemajo nefrotoksična zdravila) je tveganje za nepopolno okrevanje ledvične funkcije kljub prekinitvi uporabe dizoproksiltenofovirijevega fumarata večje (glejte poglavje 4.4).
Patients awaiting liver transplantation - Study 2025
Bolniki, ki čakajo na presaditev jeter – študija 2025
Patients awaiting liver transplantation and post-liver transplant – SOLAR-1
Bolniki, ki čakajo na presaditev jeter in bolniki po presaditvi jeter – SOLAR-1
Patients being treated with Corbilta and presenting with somnolence and/or sudden sleep onset episodes must be instructed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes have resolved (see section 4.4).
Bolnikom, ki se zdravijo z zdravilom Corbilta in navajajo pojav zaspanosti in nenadnega spanca, je treba odsvetovati da vozijo ali se udejstvujejo v dejavnostih, pri katerih lahko zaradi zmanjšane pozornosti sebe ali druge izpostavljajo nevarnosti resne poškodbe ali smrti (npr. upravljanje s stroji), vse dokler te epizode ne minejo (glejte poglavje 4.4).
Patients being treated with Levodopa and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes and somnolence have resolved (see also section 4.4)
Bolnike, ki se zdravijo z levodopo in so občutili zaspanost in/ali doživeli obdobja nenadnega uspavanja moramo obvestiti, da opustijo vožnjo ali vključevanje v dejavnosti, kjer bi zaradi zmanjšane pozornosti sebe ali druge izpostavili tveganju za resne poškodbe ali smrt (npr. upravljanje strojev), dokler taka ponavljajoča se obdobja in zaspanost ne minejo (glejte tudi poglavje 4.4).
Patients being treated with Levodopa/Carbidopa/Entacapone Orion and presenting with somnolence and/or sudden sleep onset episodes must be instructed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes have resolved (see section 4.4).
Bolnikom, ki se zdravijo z zdravilom Levodopa/Carbidopa/Entacapone Orion in navajajo pojav zaspanosti in nenadnega spanca, je treba odsvetovati da vozijo ali se udejstvujejo v dejavnostih, pri katerih lahko zaradi zmanjšane pozornosti sebe ali druge izpostavljajo nevarnosti resne poškodbe ali smrti (npr. upravljanje s stroji), vse dokler te epizode ne minejo (glejte poglavje 4.4).
Patients being treated with Oprymea and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes and somnolence have resolved (see also sections 4.4, 4.5, and 4.8).
Bolnikom, pri katerih se med zdravljenjem s pramipeksolom pojavlja zaspanost in/ali imajo nenadne epizode spanja, je treba svetovati, naj ne vozijo in naj se ne ukvarjajo z dejavnostmi, pri katerih se zaradi poslabšane budnosti poveča nevarnost resnih poškodb ali smrti (npr. pri upravljanju strojev), dokler ponavljajoče se epizode nenadnega spanja in zaspanost ne minejo (glejte poglavja 4.4, 4.5 in 4.8).
Patients being treated with Pramipexole Teva and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes and somnolence have resolved (see also sections 4.4, 4.5, and 4.8 ).
Bolnikom, ki jemljejo zdravilo Pramipeksol Teva in opažajo zaspanost ali epizode nenadnega spanca ali oboje, moramo svetovati, naj ne vozijo ali se ukvarjajo z dejavnostmi, kjer bi zmanjšana budnost lahko povzročila resne poškodbe ali smrt bolnika ali drugih (na primer pri upravljanju strojev), dokler tovrstne epizode in zaspanost ne izginejo (glejte poglavja 4.4, 4.5 in 4.8).
Patients being treated with Prolia should not be treated concomitantly with other denosumab- containing medicinal products (for prevention of skeletal related events in adults with bone metastases from solid tumours).
Bolnikov, zdravljenih z zdravilom Prolia, sočasno ne smete zdraviti z drugimi zdravili, ki vsebujejo denosumab (za preprečevanje skeletnih dogodkov pri odraslih s kostnimi metastazami solidnih tumorjev).
Patients being treated with Stalevo and presenting with somnolence and/or sudden sleep onset episodes must be instructed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes have resolved (see section 4.4).
Bolnikom, ki se zdravijo z zdravilom Stalevo in navajajo pojav zaspanosti in nenadnega spanca, je treba odsvetovati da vozijo ali se udejstvujejo v dejavnostih, pri katerih lahko zaradi zmanjšane pozornosti sebe ali druge izpostavljajo nevarnosti resne poškodbe ali smrti (npr. upravljanje s stroji), vse dokler te epizode ne minejo (glejte poglavje 4.4).
Patients being treated with Zoledronic Acid Hospira should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.
Bolniki, ki prejemajo zdravilo Zoledronska kislina Hospira, ne smejo sočasno prejemati teh zdravil ali katere koli druge difosfonate, saj skupni učinki navedenih učinkovin niso znani.
Patients being treated with Zoledronic Acid Hospira should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.
Bolniki, ki prejemajo zdravilo Zoledronska kislina Hospira, ne smejo sočasno prejemati teh zdravil ali katerih koli drugih difosfonatov, saj skupni učinki navedenih učinkovin niso znani.
Patients being treated with Zoledronic acid medac should not be treated with such products concomitantly or any other bisphosphonate, since the combined effects of these agents are unknown.
Bolniki, ki prejemajo zdravilo Zoledronska kislina medac, ne smejo sočasno prejemati takih zdravil ali katerega koli od drugih difosfonatov, saj učinki kombinacije navedenih učinkovin niso znani.
Patients being treated with Zoledronic acid Mylan should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.
Bolniki, ki prejemajo zdravilo Zoledronska kislina Mylan, ne smejo sočasno prejemati še teh zdravil ali kateregakoli od drugih difosfonatov, saj učinki kombinacije navedenih učinkovin niso znani.
Patients being treated with zoledronic acid should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.
Bolniki, ki prejemajo zdravilo Zoledronska kislina Teva Generics, ne smejo istočasno prejemati teh zdravil ali kateri koli druge difosfonate, saj skupni učinki teh zdravil niso znani.
Patients being treated with Zoledronic acid Teva should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.
Bolniki, ki prejemajo zdravilo Zoledronska kislina Teva ne smejo sočasno prejemati teh zdravil ali katerega koli od drugih difosfonatov, saj učinki kombinacije navedenih učinkovin niso znani.
Patients between 75-80 years
bolniki v starosti med 75 in 80 let,
Patients between 75-80 years should be treated with a daily dose of 300 mg taken as one 150 mg capsule twice daily.
Bolnike, stare od 75 do 80 let, je treba zdraviti z dnevnimi odmerki po 300 mg, to je eno kapsulo po 150 mg dvakrat na dan.
Patients can affix one of the peel-off labels found on the vial or pre-filled syringe to document the batch number in their diary or for reporting any side effects.
Bolniki lahko odlepijo eno od nalepk, nalepljenih na viali ali napolnjeni injekcijski brizgi, in z njo zabeležijo številko serije v svojem dnevniku ali jo uporabijo pri poročanju o morebitnih neželenih učinkih.
Patients can be switched from the immediate- to the prolonged-release tablets overnight, but the dose might need to be adjusted depending on the patient’s response.
Bolniki lahko čez noč preidejo s tablet s takojšnjim sproščanjem na tablete s podaljšanim sproščanjem, vendar bo odmerek morda treba prilagoditi glede na bolnikov odziv.
Patients can be transferred directly from other oral hypoglycaemic medicinal products to repaglinide.
Bolniki lahko preidejo na repaglinid neposredno z drugih peroralnih antidiabetikov.
Patients can experience a variety of signs and symptoms including a low red blood cell count (anaemia), the need for a blood transfusion, and a risk of infection.
Pri bolnikih se lahko pojavi vrsta različnih znakov in simptomov, vključno z zmanjšanim številom rdečih krvnh celic (anemija), potrebo po transfuziji krvi in nevarnostjo okužb.
Patients can inject Plegridy themselves, provided that they have been trained.
Bolniki si lahko zdravilo Plegridy injicirajo sami, če so bili za to ustrezno usposobljeni.
Patients can inject themselves once they have been trained appropriately.
Bolniki si lahko po primernem usposabljanju zdravilo vbrizgavajo sami.
Patients can inject themselves with NovoMix once they have been trained appropriately.
Bolniki si lahko zdravilo NovoMix po ustreznem usposabljanju vbrizgavajo sami.
Patients can inject themselves with the pre-filled syringe if they have been trained appropriately.
Bolniki si lahko zdravilo vbrizgajo sami z napolnjeno injekcijsko brizgo, če so bili za to ustrezno usposobljeni.
Patients can remain on the granules for oral suspension as long as their weight is below 20 kg.
Bolniki se lahko zdravijo z zrnci za peroralno suspenzijo vse dokler je njihova telesna masa manjša od 20 kg.
Patients can stay on apixaban while being cardioverted.
Med kardioverzijo lahko bolniki še naprej uporabljajo apiksaban.
Patients can stay on dabigatran etexilate while being cardioverted.
Bolniki lahko med kardioverzijo nadaljujejo jemanje dabigatran eteksilata.
Patients categorised as non-YMDD mutant were those with > 95% wild-type HBV at all annual time-points during the 5-year study period
Bolniki brez YMDD mutanta so bolniki, ki so med 5 letnim trajanjem študije v vseh časovnih obdobjih imeli ≥ 95 % divjega tipa HBV.
Patients changing from the twice daily dosing regimen to the once daily dosing regimen should take the recommended once daily dose (as described above) approximately 12 hours after the last twice daily dose, and then continue to take the recommended once daily dose (as described above) approximately every 24 hours.
Bolniki, ki bodo prešli z režima odmerjanja dvakrat na dan na režim odmerjanja enkrat na dan, morajo vzeti priporočeni enkratni dnevni odmerek (kot je navedeno zgoraj) približno 12 ur po zadnjem odmerku režima odmerjanja dvakrat na dan in nato nadaljevati z jemanjem priporočenega enkratnega dnevnega odmerka (kot je navedeno zgoraj) približno vsakih 24 ur.
Patients changing to AVAGLIM from sulphonylurea therapies other than glimepiride may be at an increased risk of hypoglycaemia (see section 4.4).
Bolnike, ki preidejo na AVAGLIM z drugih sulfonilsečnin kot z glimepirida, lahko bolj ogroža hipoglikemija (glejte poglavje 4.4).
Patients co-infected with HCV/HIV
Bolniki, ki imajo sočasno okužbo s HCV/HIV
Patients co-infected with hepatitis B and/or hepatitis C virus
Bolniki s sočasno okužbo z virusom hepatitisa B in/ali hepatitisa C
Patients co-infected with hepatitis B and/or hepatitis C virus
Bolniki, ki imajo sočasno okužbo z virusom hepatitisa B in/ali virusom hepatitisa C
Patients co-infected with hepatitis B and/or hepatitis C virus
Bolniki, ki so sočasno okuženi z virusom hepatitisa B in/ali virusom hepatitisa C
Patients co-infected with hepatitis B and/or hepatitis C virus
Bolniki, sočasno okuženi z virusom hepatitisa B in/ali virusom hepatitisa C
Patients co-infected with hepatitis B or C virus
Bolniki, sočasno okuženi z virusom hepatitisa B ali C
Patients co-infected with hepatitis B virus (HBV)
Bolniki, ki so okuženi hkrati še z virusom hepatitisa B (HBV)
Patients co-infected with hepatitis C and treated with alpha interferon and ribivirin may constitute a special risk.
Še posebej ogroženi so lahko bolniki, ki so hkrati okuženi z virusom hepatitisa C in zdravljeni z interferonom alfa in ribavirinom.
Patients co-infected with HIV and HBV who discontinue Descovy should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.
Bolnike s hkratno okužbo s HIV in HBV, ki prekinejo zdravljenje z zdravilom Descovy, je potrebno pozorneje opazovati in opravljati potrebne klinične in laboratorijske preiskave še vsaj nekaj mesecev po prenehanju zdravljenja.
Patients co-infected with HIV and HBV who discontinue Viread should be closely monitored with both clinical and laboratory follow-up for at least 6 months after stopping treatment.
Bolnike, ki so sočasno okuženi s HIV in HBV in prekinejo zdravljenje z zdravilom Viread, je treba skrbno nadzirati s kliničnimi in laboratorijskimi preiskavami vsaj še nadaljnjih 6 mesecev po prekinitvi zdravljenja.
Patients co-infected with HIV-1
Bolniki, sočasno okuženi z virusom HIV-1
Patients concomitantly treated with CYP1A2/2C19/3A4 inhibitors (such as fluvoxamine and cimetidine) or CYP1A2/3A4 inhibitors (such as enoxacin).
Bolniki, sočasno zdravljeni z zaviralci CYP1A2/2C19/3A4 (kot sta fluvoksamin in cimetidin) ali zaviralci CYP1A2/3A4 (kot je enoksacin).
Patients concomitantly using substrates of CYP2B6 and CYP2C9 enzymes or BCRP transporters, should be carefully monitored for adverse drug reactions.
Pri bolnikih, ki sočasno uporabljajo substrate CYP2B6 oziroma CYP2C9 ali prenašalce BCRP, je treba skrbno spremljati morebitno pojavljanje neželenih učinkov.
Patients continued in the studies for an 8 week follow-up period during which they returned for clinical observations and safety monitoring.
Bolniki so nadaljevali študiji z 8- tedenskim spremljanjem, med katerim so bili klinično opazovani, in spremljani glede varnosti.
Patients continued to receive their existing asthma medicine during the study with the exception of their OCS dose which was reduced every 4 weeks during the OCS reduction phase (Weeks 4-20), as long as asthma control was maintained.
Med študijo so še naprej uporabljali svoje dotedanje zdravilo za astmo z izjemo odmerka PKS, ki so jim ga med obdobjem zmanjševanja PKS (4. do 20. teden) zmanjšali vsake 4 tedne, če je bila astma še vedno urejena.
Patients could be enrolled only if they had experienced cardiac ischemia at rest ( 10 minutes) within the previous 24 hours and had: either ST-segment changes: ST depression > 0.5 mm of less than 30 minutes or persistent ST elevation > 0.5 mm not requiring reperfusion therapy or thrombolytic agents, T-wave inversion (> 1 mm), or increased CK-MB.
Bolniki so bili lahko v to študijo vključeni le, če so imeli v preteklih 24 urah ishemijo miokarda v mirovanju (≥ 10 minut) in: bodisi spremembe spojnice ST: znižanje spojnice ST za > 0,5 mm za manj kot 30 minut ali trdovratno zvišanje spojnice ST za > 0,5 mm, ki ni zahtevalo reperfuzijske terapije ali trombolitičnih zdravil, inverzijo vala T (> 1 mm), ali povečanje vrednosti CK-MB.
Patients could be recommended to self-inject the product when they are judged willing and able to do so.
Bolnikom se lahko svetuje, da si sami injicirajo zdravilo, če se presodi, da so pripravljeni in sposobni za to.
Patients could not be seizure-free for 21 days.
Bolniki niso smeli biti brez napadov  21 dni.
Patients currently dependent on chronic opioids (see sections 4.4 and 4.5) or opiate agonists (e.g., methadone), or patients in acute opiate withdrawal
Bolniki, ki so trenutno odvisni od kroničnega zdravljenja z opioidi (glejte poglavji 4.4 in 4.5) ali opiatnimi agonisti (npr. metadonom), ali bolniki, ki prestajajo akutno odtegnitev opiatov
Patients currently treated with an ESA can be switched to MIRCERA administered once a month as a single intravenous or subcutaneous injection.
Bolniki, ki se trenutno zdravijo z zdravili za stimulacijo eritropoeze, lahko preidejo na zdravilo MIRCERA z odmerjanjem enkrat na mesec v eni intravenski ali subkutani injekciji.
Patients currently treated with an ESA:
Bolniki, ki se trenutno zdravijo z zdravili za stimulacijo eritropoeze
Patients demonstrating a Pediatric ACR 30 response at Week 16 were eligible to be randomised into the double blind (DB) phase and received either Humira 24 mg/m2 up to a maximum of 40 mg, or placebo every other week for an additional 32 weeks or until disease flare.
Bolniki, ki so 16. teden dosegli odziv »Pediatric ACR« 30, so bili primerni za randomizacijo v dvojno slepo fazo in so nadaljnjih 32 tednov ali do zagona bolezni vsak drugi teden dobili zdravilo Humira 24 mg/m2 (do največ 40 mg) ali placebo.
Patients demonstrating a subsequent increase in QT-interval to > 480 msec or prolongation over pre-treatment by > 20 msec should discontinue ritonavir-boosted Invirase.
Bolniki, ki imajo kasnejšo porast intervala QT na > 480 msec ali podaljšanje intervala QT za > 20 msec od stanja pred zdravljenjem, morajo zdravljenje z zdravilom Invirase s podporno terapijo z ritonavirjem prekiniti.
Patients designated as YMDD mutant were those with 5% YMDD mutant HBV at any annual time-point during the 5-year period.
Bolniki z YMDD mutantom so bolniki, ki so v obdobju 5-ih let imeli v katerem koli časovnem obdobju ≥ 5 % YMDD mutanta HBV.
Patients designated as YMDD mutant were those with 5% YMDD mutant HBV at any annual time-point during the 5-year period.
Bolniki z YMDD mutantom so bolniki, ki so v obdobju 5-ih let imeli v kateremkoli časovnem obdobju ≥ 5 % YMDD mutana HBV.
Patients developing Factor VIII inhibitors
Bolniki, pri katerih se pojavijo zaviralci faktorja VIII
Patients developing inhibitory antibodies to OBIZUR
Bolniki, pri katerih se pojavijo inhibitorna protitelesa proti zdravilu OBIZUR
Patients developing PRES/RPLS should permanently discontinue treatment with pazopanib.
Bolniki, ki se jim pojavi PRES/RPLS, morajo trajno prenehati zdravljenje s pazopanibom.
Patients developing TMA should permanently discontinue treatment with pazopanib.
Bolniki, ki se jim pojavi TMA, morajo trajno prenehati zdravljenje s pazopanibom.
Patients diagnosed with hepatic impairment while receiving Jakavi should have complete blood counts, including a white blood cell count differential, monitored at least every one to two weeks for the first 6 weeks after initiation of therapy with Jakavi and as clinically indicated thereafter once their liver function and blood counts have been stabilised.
Pri bolnikih, pri katerih odkrijejo okvaro jeter v času zdravljenja z zdravilom Jakavi, je treba spremljati celotno krvno sliko, vključno z diferencialno belo krvno sliko, najmanj na en do dva tedna v prvih 6 tednih po začetku zdravljenja z zdravilom Jakavi, kasneje, ko se jetrna funkcija in število krvnih celic stabilizirata, pa glede na klinične indikacije.
patients diagnosed with or being treated for cancer;
pri bolnikih, pri katerih je bil diagnosticiran rak ali se zdravijo zaradi raka;
Patients diagnosed with pulmonary hypertension, in particular, should receive adequate doses of Cerezyme to ensure control of underlying Gaucher disease as well as be evaluated for the need of additional pulmonary hypertension specific treatments.
Za bolnike z diagnozo pljučne hipertenzije še posebno velja, da morajo prejemati ustrezne odmerke zdravila Cerezyme za zagotovitev nadzora Gaucherjeve bolezni, hkrati pa se morajo izvajati pregledi, da se ugotovi, če so potrebna dodatna, posebna zdravljenja za pljučno hipertenzijo.
Patients diagnosed with relapsing multiple sclerosis (MS).
bolnikov z diagnozo ponavljajoče se multiple skleroze (MS).
Patients enrolled in aHUS C10-003 had an ADAMTS-13 level above 5%.
Bolniki, vključeni v študijo aHUS C10-003, so imeli raven ADAMTS-13 nad 5 %.
Patients enrolled in this study had active disease (defined as a BASDAI ≥ 4 and a Visual Analogue Scale (VAS) for total back pain of ≥ 4, each on a scale of cm) despite current or previous NSAID therapy and had not previously been treated with any biological agents including anti-TNF therapy.
Bolniki, vključeni v to študijo, so imeli aktivno bolezen (opredeljeno z BASDAI ≥ 4 in oceno vseh bolečin v hrbtu na vizualni analogni skali (VAS) ≥ 4, vsako na lestvici od 0 do 10 cm) kljub trenutnemu ali predhodnemu zdravljenju z NSAID ter se predhodno niso zdravili z nobenim biološkim zdravilom, vključno z zdravili proti TNF.
Patients enrolled into the epoprostenol add-on therapy study were eligible to enter a long term open label extension study.
Bolniki, vključeni v študijo, v kateri so kot dodatno zdravljenje prejemali še epoprostenol, so bili primerni za dolgoročno odprto podaljšano študijo.
Patients enrolled into the pivotal oral route study were eligible to enter a long term open label extension study.
Bolniki, vključeni v ključno študijo po peroralni poti, so bili primerni za dolgoročno odprto podaljšano študijo.
Patients entered an open label long-term extension at week 52.
V 52. tednu pa so ti bolniki vstopili v odprto, dolgoročno podaljšanje študije.
Patients established on triple oral therapy: when appropriate, AVANDAMET may substitute rosiglitazone and metformin doses already being taken.
Bolniki, ki se jim uvede zdravljenje s tremi zdravili: če je primerno, lahko zdravilo AVANDAMET zamenja odmerke rosiglitazona in metformina, ki jih je bolnik že jemal.
patients exhibited withdrawal
Na začetku ali ob prenehanju
Patients experiencing a laryngeal attack should always seek medical advice and be observed in a medical institution also after having taken the injection at home.
Bolnik z laringealnim napadom se mora vedno obrniti na zdravnika in ga je treba opazovati v zdravstveni ustanovi, tudi če si je zdravilo injiciral že doma.
Patients experiencing a severe flare (%)
Bolniki, ki se jim je pojavilo poslabšanje (%)